Latest Healthcare News

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

Universal Biosensors updates investors on a shift from a secured loan to a potential entitlement offer, signaling evolving funding strategies and extended timelines.

IDT Australia announces the immediate resignation of CEO Paul McDonald, appointing Executive Chair Mark Simari to lead as the company reports a 40.6% revenue increase but a widening net loss for FY25.

Atomo Diagnostics has secured a US$410,000 order from Lumos Diagnostics for its Pascal test cassettes, following Lumos's exclusive six-year US distribution deal for the FebriDx test with PHASE Scientific.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Nanoveu Limited advances its proprietary 16nm ECS-DoT chip fabrication, targeting completion by Q4 2025, supported by a strategic partnership and expanded engineering teams across multiple continents.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Nutritional Growth Solutions Ltd (NGS) has had its trading suspension lifted following a key announcement about a capital raising, signaling renewed market activity.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Nutritional Growth Solutions Ltd has voluntarily suspended trading on the ASX pending a capital raising announcement, signaling a pivotal moment for the pediatric nutrition company.